Janssen Escapes Whistleblower Suit Over Off-Label Opioids
A California federal judge Thursday nixed a False Claims Act suit accusing Johnson & Johnson subsidiary Janssen Pharmaceutical NV of using unlawful marketing practices to boost off-label sales of its opioid...To view the full article, register now.
Already a subscriber? Click here to view full article